Mental Health, Advanced Pharmacotherapeutics, & Precision Medicine Bundle 2024
Expiration Date: December 31, 2025
Total Credits: 14.25 contact hours; 11.50 are pharmacology
Expiration Date: December 31st, 2025
Bundle Description
This learning workshop is an amazing, unique, and dynamic CE package bringing together cutting-edge evidence and new approaches to mental health prescribing. This workshop is exclusive to NPACE. Under the guidance of Dr. Josh Hamilton, DNP, RN-BC, FNP-C, PMHNP-BC, CNE, FAANP an expert clinician and mental health practitioner. Learners will step through this education beginning with a call to action, moving to foundational concepts and pathophysiology, and then advance from common to more complex mental health conditions in prescribing methodology through the lens of precision healthcare. how to prescribe effectively through. At the completion of this package the learner will not only earn credits, but earn a certificate of completion in Mental Health Pharmacotheraputics and Precision medicine.
Bundle Content includes:
- NPACE KEYNOTE: Renewing the Primary Care Commitment to Mental Health
- Realizing the Potential of Rapid-Acting Treatments for Depression
- Precision Healthcare for Impaired Reality Testing
- Epigenetics, Neuroplasticity & Mental Health Interventions
- Precision Medicine: Genomically-Informed Pain Management Strategies
- Precisions Medicine for Substance Use Disorders
- The Basics of Precision Healthcare: Introduction to Psychiatric Pharmacogenonics
- Precision Medicine for Trauma & Stressor-Related Disorders
- Precision Medicine: Personalized Treatment of Depression
- Neurobiology & Personalized Treatment of Anxiety Disorders
- To Prescribe or Not to Prescribe? Benzodiazepines in an Era of Prescription Drug Abuse
- Neurobiology, Genomics & Precision Medicine for Bipolar Disorders
- Precision Medicine for ADHD: Genetics, Neurobiology & Treatment
- Bundle Evaluation & Certificate: Mental Health, Advanced Pharmacotherapeutics, & Precision Medicine Bundle 2024
NPACE KEYNOTE: Renewing the Primary Care Commitment to Mental Health
This keynote discussion surfaces issues related integrated mental health and primary care. Two career nurse practitioners discuss key concepts of integrated healthcare, including tips and practice pearls for nurse practitioners who are striving to address the mental health concerns of patients in the primary care context.
Credits: 1.50 Contact Hours; 0.50 are Pharmacology
Learning Objectives
After taking part in this educational activity, participants should be better able to:
- Understand and discuss the burden of mental illness, relative to the logical access point of primary care
- Explore practical approaches to mental healthcare integration in primary care
- Define psychometry and its use in screening, diagnosis, and ongoing measurement-based care
- Develop shared decision-making framework for approaching mental health issues in the primary care setting
- Operationalize a plan to address red flags and referrals in integrated mental health/primary care settings
Speaker
Josh Hamilton, DNP, RN-BC, FNP-C, PMHNP-BC, CTMH, CNE, FAANP
President & Chief Clinical Officer
The Hamilton Group LLC
Dr. Josh Hamilton bases his clinical practice in Las Vegas, NV. With more than two decades of nursing experience, he also holds professorial appointments, leadership positions and consults extensively in the higher education space. Previously, he was Associate Medical Director for the largest managed care behavioral health network in the Desert Southwest. He served on the Nevada Board of Nursing’s Advanced Practice and Educational Advisory Committees and spearheaded the Donate Life campaign at the state level.
His professional interests include neurobiology, pharmacology and epigenetics. He is an internationally-recognized speaker on these (and related) topics at conferences and professional meetings. He works with a variety of organizations to develop, review and present live and enduring continuing education activities. Engagements include the American Association of Nurse Practitioners, Myriad Neuroscience, MedIQ, Nurse Practitioner Continuing Education Associates (NPACE), and Vindico Medical Education. He serves on the psychiatric medication working group at the Center of Excellence in Regulatory Science & Innovation, a FDA-sponsored project at the University of Maryland.
Dr. Hamilton earned his doctorate in nursing from Rush University in Chicago. At the University of Wyoming, he earned a baccalaureate degree in Natural Science and Mathematics as well as a master’s degree in Nursing. He also has an undergraduate degree in Biology. He is nationally certified as a psychiatric-mental health nurse; family nurse practitioner; family psychiatric nurse practitioner, telemental healthcare provider, and nurse educator. He was recognized as a doctoral scholar by the National League for Nursing, and he is a fellow of the American Association of Nurse Practitioners. He was recognized for establishing a unique clinic structure that improves access to cost-effective, convenient, quality mental healthcare. His academic connections fostered synergies and renewed attention to nursing education that focuses on care for the vulnerable mentally ill population in Nevada and across the nation. Dr. Hamilton is also a master clinical psychopharmacologist (through the Neuroscience Education Institute), and he was the 2015 Distinguished Alumnus at his alma mater, the University of Wyoming. He is the Nevada state representative for AANP.
A classically trained pianist, Dr. Hamilton enjoys live music, international travel and automobiles. He is an active supporter of local animal rescue and rehoming efforts, as well as charities that provide critical transportation for patients in need of distant life-saving specialty healthcare. Dr. Hamilton grew up in Casper, Wyoming, with his sights set on medical school. He originally pursued a nursing degree thinking the experience would make him a better physician. Along the way, he discovered an affinity and passion for the humanistic, health-promoting philosophy of nursing. He has since devoted his career to clinical practice, furthering the cause of the profession and educating future leaders in the healthcare field.
Learn more about Dr. Josh Hamilton at www.linkedin.com/in/hamiltondnp
CE Information
Obtain Your Credits
To earn credits for this activity, navigate to the Content(s) tab and complete all course components in the following order: 1) watch the course presentation video; 2) complete the course evaluation; 3) pass the post-test with a score of 2/3 (66.7%) or higher. You may retake the post-test until a passing score is achieved, at which point you will be able to view/print a copy of your certificate of completion. This online certificate will also be saved within your profile 'My Dashboard' -> 'Transcript/Certificates Earned' for future access.
Designation Statement
NPACE designates this educational activity for a maximum of 1.50 contact hours, of which 0.50 is pharmacology credit. Participants should claim only credit commensurate with the extent of their participation in the activity.
Accreditation Statement
Nurse Practitioner Associates for Continuing Education (NPACE) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).
In addition to ANCC, NPACE is approved as a provider of continuing education in nursing by: the California Board of Registered Nursing, Provider Number CEP8720 and Florida CE Broker #50-1476.
Disclosure
Faculty
Contributing faculty, Josh Hamilton, DNP, RN-BC, FNP-C, PMHNP-BC, CNE, FAANP have disclosed:
Myriad Neuroscience, Speakers Bureau (ended 08/2023), PGx Testing Genesight
Tempus Labs, Inc., Consultant & Speakers Bureau, PGx Testing Tempus nP
Point of Care Network, Paid Ambassador, Various N/A
Planners
All planners and contributors involved in this educational activity have disclosed no relevant financial relationships.
Disclaimer
The material presented in this continuing education program is being made available for educational purposes only and is not intended to represent the best or only methods, medications and/or guidelines appropriate for the medical situation discussed. Rather the material is intended to present an approach, view, statement, or opinion of the presenter(s), which may be helpful, or of interest to other practitioners and should not be used by clinicians without the evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. NPACE disclaims any liability, loss, injury, or damage incurred as a consequence, directly or indirectly, of the use and application of any information given in a presentation.
Disclosure of Unlabeled Use
This educational activity may mention the uses of products that are not approved by the FDA for the indication(s) being discussed. The presenter(s) are instructed to notify participants when they are discussing unapproved uses or investigational agents. The opinions related to unapproved uses of products are solely those of the presenter(s) and are not endorsed or recommended by NPACE. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Commercial Support
There is no commercial support for this activity
Realizing the Potential of Rapid-Acting Treatments for Depression
Optimal management of depression begins with adequate screening and early introduction of appropriate therapy; however, monoaminergic antidepressants, which are currently considered the standard of care, have several limitations, including low therapeutic response times, suboptimal efficacy and remission rates, and adverse effects that may impact patient adherence. This session explores novel pathways involved in the etiology of depression, including glutamatergic and GABAergic modulation. Newer pharmacologic agents, including neuroactive steroids and glutamatergic antidepressants are introduced; practical considerations for nurse practitioners are presented and applied to real-world cases.
Credits: 1.25 Contact Hours; 1.00 are PharmacologyLearning Objectives
After taking part in this educational activity, participants should be better able to:
- Improve understanding of the mechanisms of action of novel rapid-acting pharmacotherapies for depression.
- Increase knowledge about the efficacy and unique safety profiles associated with novel antidepressants.
- Augment the clinician’s ability to select appropriate patients for treatment with rapid-acting antidepressants
- Equip the clinician with the skills needed to engage in shared decision making to optimize patient outcomes
Speaker
Josh Hamilton, DNP, RN-BC, FNP-C, PMHNP-BC, CTMH, CNE, FAANP
President & Chief Clinical Officer
The Hamilton Group LLC
CE Information
Obtain Your Credits
To earn credits for this activity, navigate to the Content(s) tab and complete all course components in the following order: 1) watch the course presentation video; 2) complete the course evaluation; 3) pass the post-test with a score of 2/3 (66.7%) or higher. You may retake the post-test until a passing score is achieved, at which point you will be able to view/print a copy of your certificate of completion. This online certificate will also be saved within your profile 'My Dashboard' -> 'Transcript/Certificates Earned' for future access.
Designation Statement
NPACE designates this educational activity for a maximum of 1.25 contact hours, of which 1.00 is pharmacology credit. Participants should claim only credit commensurate with the extent of their participation in the activity.
Accreditation Statement
Nurse Practitioner Associates for Continuing Education (NPACE) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).
In addition to ANCC, NPACE is approved as a provider of continuing education in nursing by: the California Board of Registered Nursing, Provider Number CEP8720 and Florida CE Broker #50-1476.
Disclosure
Faculty
Contributing faculty, Josh Hamilton, DNP, RN-BC, FNP-C, PMHNP-BC, CNE, FAANP have disclosed:
Myriad Neuroscience, Speakers Bureau (ended 08/2023), PGx Testing Genesight
Tempus Labs, Inc., Consultant & Speakers Bureau, PGx Testing Tempus nP
Point of Care Network, Paid Ambassador, Various N/A
Planners
All planners and contributors involved in this educational activity have disclosed no relevant financial relationships.
Disclaimer
The material presented in this continuing education program is being made available for educational purposes only and is not intended to represent the best or only methods, medications and/or guidelines appropriate for the medical situation discussed. Rather the material is intended to present an approach, view, statement, or opinion of the presenter(s), which may be helpful, or of interest to other practitioners and should not be used by clinicians without the evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. NPACE disclaims any liability, loss, injury, or damage incurred as a consequence, directly or indirectly, of the use and application of any information given in a presentation.
Disclosure of Unlabeled Use
This educational activity may mention the uses of products that are not approved by the FDA for the indication(s) being discussed. The presenter(s) are instructed to notify participants when they are discussing unapproved uses or investigational agents. The opinions related to unapproved uses of products are solely those of the presenter(s) and are not endorsed or recommended by NPACE. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Commercial Support
There is no commercial support for this activity
Precision Healthcare for Impaired Reality Testing
This session explores the presentation and treatment of psychotic symptoms. Focus is directed to the treatment of schizophrenia, an incurable neuropsychiatric disorder. Up to 34% of patients with schizophrenia have treatment-resistant schizophrenia. Most current treatments for schizophrenia have focused exclusively on dopamine, which can improve the positive symptoms of schizophrenia; however, these therapies are often associated with adverse effects. None of the currently available therapies were designed to specifically target the negative symptoms of schizophrenia. Recently, the development and investigation of agents targeting the muscarinic system have demonstrated that these agents may be viable treatment options for patients with schizophrenia and have been shown to improve the negative symptoms of schizophrenia. This session assesses the symptom and treatment burdens faced by patients with schizophrenia and examines the mechanisms of action, safety, and efficacy of emerging agents with novel therapeutic targets to treat all symptoms associated with schizophrenia.
Credits: 1.25 Contact Hours; 1.00 are Pharmacology
Learning Objectives
After taking part in this educational activity, participants should be better able to:
- Conceptualize mental illness in a neurobiological context (with an emphasis on psychotic disorders).
- Discuss current approaches to management of psychotic disorders, including practical applications for nurse practitioners.
- Apply concepts of pharmacogenomics to the selection, prescription and management of drug therapy for psychotic disorders.
- Explore and discuss novel pipeline pharmacotherapeutics for the treatment of psychosis.
Speaker
Josh Hamilton, DNP, RN-BC, FNP-C, PMHNP-BC, CTMH, CNE, FAANP
President & Chief Clinical Officer
The Hamilton Group LLC
CE Information
Obtain Your Credits
To earn credits for this activity, navigate to the Content(s) tab and complete all course components in the following order: 1) watch the course presentation video; 2) complete the course evaluation; 3) pass the post-test with a score of 2/3 (66.7%) or higher. You may retake the post-test until a passing score is achieved, at which point you will be able to view/print a copy of your certificate of completion. This online certificate will also be saved within your profile 'My Dashboard' -> 'Transcript/Certificates Earned' for future access.
Designation Statement
NPACE designates this educational activity for a maximum of 1.25 contact hours, of which 1.00 is pharmacology credit. Participants should claim only credit commensurate with the extent of their participation in the activity.
Accreditation Statement
Nurse Practitioner Associates for Continuing Education (NPACE) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).
In addition to ANCC, NPACE is approved as a provider of continuing education in nursing by: the California Board of Registered Nursing, Provider Number CEP8720 and Florida CE Broker #50-1476.
Disclosure
Faculty
Contributing faculty, Josh Hamilton, DNP, RN-BC, FNP-C, PMHNP-BC, CNE, FAANP have disclosed:
Myriad Neuroscience, Speakers Bureau (ended 08/2023), PGx Testing Genesight
Tempus Labs, Inc., Consultant & Speakers Bureau, PGx Testing Tempus nP
Point of Care Network, Paid Ambassador, Various N/A
Planners
All planners and contributors involved in this educational activity have disclosed no relevant financial relationships.
Disclaimer
The material presented in this continuing education program is being made available for educational purposes only and is not intended to represent the best or only methods, medications and/or guidelines appropriate for the medical situation discussed. Rather the material is intended to present an approach, view, statement, or opinion of the presenter(s), which may be helpful, or of interest to other practitioners and should not be used by clinicians without the evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. NPACE disclaims any liability, loss, injury, or damage incurred as a consequence, directly or indirectly, of the use and application of any information given in a presentation.
Disclosure of Unlabeled Use
This educational activity may mention the uses of products that are not approved by the FDA for the indication(s) being discussed. The presenter(s) are instructed to notify participants when they are discussing unapproved uses or investigational agents. The opinions related to unapproved uses of products are solely those of the presenter(s) and are not endorsed or recommended by NPACE. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Commercial Support
There is no commercial support for this activity
Epigenetics, Neuroplasticity & Mental Health Interventions
In this foundational course, Dr. Josh Hamilton reviews what epigentics is, why it matters in the development disease, and in what pathways. Learners are encouraged to brush up on cell biology a bit with this presentation and are introduced to topics like: Posttranslational gene modification, acetylation, methylation, ubiquination, and more. Learn about neurohormonal stress, the importance of brain development, pleiotropy and more! This course is critical for all NPs to understand how disease develops and can be passed on to offspring.
Credits: 1.00 Contact Hours; 0.50 are Pharmacology
Learning Objectives
After taking part in this educational activity, participants should be better able to:
- Define the common factors in the therapeutic framework.
- Discuss theories of pathologic neurobiology in psychiatry.
- Propose and discuss neurobiological mechanisms of action for various therapeutic approaches.
Speaker
Josh Hamilton, DNP, RN-BC, FNP-C, PMHNP-BC, CTMH, CNE, FAANP
President & Chief Clinical Officer
The Hamilton Group LLC
CE Information
Obtain Your Credits
To earn credits for this activity, navigate to the Content(s) tab and complete all course components in the following order: 1) watch the course presentation video; 2) complete the course evaluation; 3) pass the post-test with a score of 2/3 (66.7%) or higher. You may retake the post-test until a passing score is achieved, at which point you will be able to view/print a copy of your certificate of completion. This online certificate will also be saved within your profile 'My Dashboard' -> 'Transcript/Certificates Earned' for future access.
Designation Statement
NPACE designates this educational activity for a maximum of 1.25 contact hours, of which 1.00 is pharmacology credit. Participants should claim only credit commensurate with the extent of their participation in the activity.
Accreditation Statement
Nurse Practitioner Associates for Continuing Education (NPACE) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).
In addition to ANCC, NPACE is approved as a provider of continuing education in nursing by: the California Board of Registered Nursing, Provider Number CEP8720 and Florida CE Broker #50-1476.
Disclosure
Faculty
Contributing faculty, Josh Hamilton, DNP, RN-BC, FNP-C, PMHNP-BC, CNE, FAANP have disclosed:
Myriad Neuroscience, Speakers Bureau (ended 08/2023), PGx Testing Genesight
Tempus Labs, Inc., Consultant & Speakers Bureau, PGx Testing Tempus nP
Point of Care Network, Paid Ambassador, Various N/A
Planners
All planners and contributors involved in this educational activity have disclosed no relevant financial relationships.
Disclaimer
The material presented in this continuing education program is being made available for educational purposes only and is not intended to represent the best or only methods, medications and/or guidelines appropriate for the medical situation discussed. Rather the material is intended to present an approach, view, statement, or opinion of the presenter(s), which may be helpful, or of interest to other practitioners and should not be used by clinicians without the evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. NPACE disclaims any liability, loss, injury, or damage incurred as a consequence, directly or indirectly, of the use and application of any information given in a presentation.
Disclosure of Unlabeled Use
This educational activity may mention the uses of products that are not approved by the FDA for the indication(s) being discussed. The presenter(s) are instructed to notify participants when they are discussing unapproved uses or investigational agents. The opinions related to unapproved uses of products are solely those of the presenter(s) and are not endorsed or recommended by NPACE. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Commercial Support
There is no commercial support for this activity
Precision Medicine: Genomically-Informed Pain Management Strategies
Every day, more than 90 Americans die after overdosing on opioids. The misuse of opioids is a serious national crisis that affects public health as well as social and economic welfare. The Centers for Disease Control and Prevention estimates that the total economic burden of prescription opioid misuse in the United States exceeds $78.5 billion annually, including the costs of healthcare, lost productivity, addiction treatment, and criminal justice involvement. The knowledge and application of pharmacogenomics to the treatment of pain operationalizes one of the major priorities of the Department of Health & Human Services to address the opioid crisis.
Credits: 1.00 Contact Hours; 0.75 are Pharmacology
Learning Objectives
After taking part in this educational activity, participants should be better able to:
- Compare and contrast treatment-as-usual and precision approaches to pain management.
- Explore concepts of pharmacogenomics in the context of pain management.
- Analyze and select various analgesic agents based upon pharmacokinetic and pharmacodynamic properties.
Speaker
Josh Hamilton, DNP, RN-BC, FNP-C, PMHNP-BC, CTMH, CNE, FAANP
President & Chief Clinical Officer
The Hamilton Group LLC
CE Information
Obtain Your Credits
To earn credits for this activity, navigate to the Content(s) tab and complete all course components in the following order: 1) watch the course presentation video; 2) complete the course evaluation; 3) pass the post-test with a score of 2/3 (66.7%) or higher. You may retake the post-test until a passing score is achieved, at which point you will be able to view/print a copy of your certificate of completion. This online certificate will also be saved within your profile 'My Dashboard' -> 'Transcript/Certificates Earned' for future access.
Designation Statement
NPACE designates this educational activity for a maximum of 1.25 contact hours, of which 1.00 is pharmacology credit. Participants should claim only credit commensurate with the extent of their participation in the activity.
Accreditation Statement
Nurse Practitioner Associates for Continuing Education (NPACE) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).
In addition to ANCC, NPACE is approved as a provider of continuing education in nursing by: the California Board of Registered Nursing, Provider Number CEP8720 and Florida CE Broker #50-1476.
Disclosure
Faculty
Contributing faculty, Josh Hamilton, DNP, RN-BC, FNP-C, PMHNP-BC, CNE, FAANP have disclosed:
Myriad Neuroscience, Speakers Bureau (ended 08/2023), PGx Testing Genesight
Tempus Labs, Inc., Consultant & Speakers Bureau, PGx Testing Tempus nP
Point of Care Network, Paid Ambassador, Various N/A
Planners
All planners and contributors involved in this educational activity have disclosed no relevant financial relationships.
Disclaimer
The material presented in this continuing education program is being made available for educational purposes only and is not intended to represent the best or only methods, medications and/or guidelines appropriate for the medical situation discussed. Rather the material is intended to present an approach, view, statement, or opinion of the presenter(s), which may be helpful, or of interest to other practitioners and should not be used by clinicians without the evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. NPACE disclaims any liability, loss, injury, or damage incurred as a consequence, directly or indirectly, of the use and application of any information given in a presentation.
Disclosure of Unlabeled Use
This educational activity may mention the uses of products that are not approved by the FDA for the indication(s) being discussed. The presenter(s) are instructed to notify participants when they are discussing unapproved uses or investigational agents. The opinions related to unapproved uses of products are solely those of the presenter(s) and are not endorsed or recommended by NPACE. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Commercial Support
There is no commercial support for this activity
Precision Medicine for Substance Use Disorders
This presentation reframes and reinforces a working knowledge of substance use and dependence in a neurobiological context. Updated disease models are presented as the basis for development of pragmatic clinical approaches. Concepts of pharmacogenomics and personalized medicine are applied to diagnosis and treatment of this challenging set of clinical issues.
Credits: 1.00 Contact Hours; 1.00 are Pharmacology
Learning Objectives
After taking part in this educational activity, participants should be better able to:
- Conceptualize alcohol abuse & opioid dependence in the context of neurobiology.
- Analyze the role of genetics in the etiology, assessment & treatment of substance abuse.
- Explore the utility of pharmacogenomic testing in assessment and treatment decisions.
- Operationalize a pragmatic approach to prescribing and managing drug treatment for a variety of patient populations.
Speaker
Josh Hamilton, DNP, RN-BC, FNP-C, PMHNP-BC, CTMH, CNE, FAANP
President & Chief Clinical Officer
The Hamilton Group LLC
CE Information
Obtain Your Credits
To earn credits for this activity, navigate to the Content(s) tab and complete all course components in the following order: 1) watch the course presentation video; 2) complete the course evaluation; 3) pass the post-test with a score of 2/3 (66.7%) or higher. You may retake the post-test until a passing score is achieved, at which point you will be able to view/print a copy of your certificate of completion. This online certificate will also be saved within your profile 'My Dashboard' -> 'Transcript/Certificates Earned' for future access.
Designation Statement
NPACE designates this educational activity for a maximum of 1.00 contact hours, of which 1.00 is pharmacology credit. Participants should claim only credit commensurate with the extent of their participation in the activity.
Accreditation Statement
Nurse Practitioner Associates for Continuing Education (NPACE) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).
In addition to ANCC, NPACE is approved as a provider of continuing education in nursing by: the California Board of Registered Nursing, Provider Number CEP8720 and Florida CE Broker #50-1476.
Disclosure
Faculty
Contributing faculty, Josh Hamilton, DNP, RN-BC, FNP-C, PMHNP-BC, CNE, FAANP have disclosed:
Myriad Neuroscience, Speakers Bureau (ended 08/2023), PGx Testing Genesight
Tempus Labs, Inc., Consultant & Speakers Bureau, PGx Testing Tempus nP
Point of Care Network, Paid Ambassador, Various N/A
Planners
All planners and contributors involved in this educational activity have disclosed no relevant financial relationships.
Disclaimer
The material presented in this continuing education program is being made available for educational purposes only and is not intended to represent the best or only methods, medications and/or guidelines appropriate for the medical situation discussed. Rather the material is intended to present an approach, view, statement, or opinion of the presenter(s), which may be helpful, or of interest to other practitioners and should not be used by clinicians without the evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. NPACE disclaims any liability, loss, injury, or damage incurred as a consequence, directly or indirectly, of the use and application of any information given in a presentation.
Disclosure of Unlabeled Use
This educational activity may mention the uses of products that are not approved by the FDA for the indication(s) being discussed. The presenter(s) are instructed to notify participants when they are discussing unapproved uses or investigational agents. The opinions related to unapproved uses of products are solely those of the presenter(s) and are not endorsed or recommended by NPACE. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Commercial Support
There is no commercial support for this activity
The Basics of Precision Healthcare: Introduction to Psychiatric Pharmacogenomics
The pharmacology of psychotropics is complex, and one of the most contemporary tools available to facilitate clinical decision-making is Precision Medicine. Based in pharmacogenomics, this approach combines pharmacology (the study of medication) and genomics (the study of genes and their functions) to help prescribers make more personalized medication choices. This session lays the groundwork for these concepts as the basis for a multitude of applications in precision mental healthcare.
Credits: 0.50 Contact Hours; 0.50 are Pharmacology
Learning Objectives
After taking part in this educational activity, participants should be better able to:
- Review basic genetics concepts to establish the foundation for pharmacogenomics.
- Define, discuss and develop the concept of “pharmacogenomics” as it relates to mental healthcare.
- Explore medication dynamics and kinetics in the context of genomics.
Speaker
Josh Hamilton, DNP, RN-BC, FNP-C, PMHNP-BC, CTMH, CNE, FAANP
President & Chief Clinical Officer
The Hamilton Group LLC
CE Information
Obtain Your Credits
To earn credits for this activity, navigate to the Content(s) tab and complete all course components in the following order: 1) watch the course presentation video; 2) complete the course evaluation; 3) pass the post-test with a score of 2/3 (66.7%) or higher. You may retake the post-test until a passing score is achieved, at which point you will be able to view/print a copy of your certificate of completion. This online certificate will also be saved within your profile 'My Dashboard' -> 'Transcript/Certificates Earned' for future access.
Designation Statement
NPACE designates this educational activity for a maximum of 0.50 contact hours, of which 0.50 is pharmacology credit. Participants should claim only credit commensurate with the extent of their participation in the activity.
Accreditation Statement
Nurse Practitioner Associates for Continuing Education (NPACE) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).
In addition to ANCC, NPACE is approved as a provider of continuing education in nursing by: the California Board of Registered Nursing, Provider Number CEP8720 and Florida CE Broker #50-1476.
Disclosure
Faculty
Contributing faculty, Josh Hamilton, DNP, RN-BC, FNP-C, PMHNP-BC, CNE, FAANP have disclosed:
Myriad Neuroscience, Speakers Bureau (ended 08/2023), PGx Testing Genesight
Tempus Labs, Inc., Consultant & Speakers Bureau, PGx Testing Tempus nP
Point of Care Network, Paid Ambassador, Various N/A
Planners
All planners and contributors involved in this educational activity have disclosed no relevant financial relationships.
Disclaimer
The material presented in this continuing education program is being made available for educational purposes only and is not intended to represent the best or only methods, medications and/or guidelines appropriate for the medical situation discussed. Rather the material is intended to present an approach, view, statement, or opinion of the presenter(s), which may be helpful, or of interest to other practitioners and should not be used by clinicians without the evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. NPACE disclaims any liability, loss, injury, or damage incurred as a consequence, directly or indirectly, of the use and application of any information given in a presentation.
Disclosure of Unlabeled Use
This educational activity may mention the uses of products that are not approved by the FDA for the indication(s) being discussed. The presenter(s) are instructed to notify participants when they are discussing unapproved uses or investigational agents. The opinions related to unapproved uses of products are solely those of the presenter(s) and are not endorsed or recommended by NPACE. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Commercial Support
There is no commercial support for this activity
Precision Medicine for Trauma & Stressor-Related Disorders
Updated diagnostic criteria and disease models for trauma and stressor-related disorders are reviewed. Neurobiological and epigenetic mechanisms that underlie stressor-related symptoms are presented as the basis for therapeutic interventions. Specific attention is given to the formulation of rational, genomically-informed pharmacologic treatment approaches for trauma and stressor-related disorders. Practical applications for nurse practitioners are presented.
Credits: 1.50 Contact Hours; 1.25 are Pharmacology
Learning Objectives
After taking part in this educational activity, participants should be better able to:
- Conceptualize mental illness in the context of epi/genetics and neurobiology, with an emphasis on stressor-related disorders.
- Develop a working knowledge of updated diagnostic criteria and disease models to improve case identification and diagnosis of stressor-related disorders.
- Discuss contemporary approaches to management of stressor-related disorders, including practical applications for nurse practitioners.
- Explore evidence- and eminence-based polypharmaceutical approaches to selection and monitoring of treatments for trauma.
- Apply concepts of pharmacogenomics to the selection, prescription and management of drug therapy for stressor-related disorders.
Speaker
Josh Hamilton, DNP, RN-BC, FNP-C, PMHNP-BC, CTMH, CNE, FAANP
President & Chief Clinical Officer
The Hamilton Group LLC
CE Information
Obtain Your Credits
To earn credits for this activity, navigate to the Content(s) tab and complete all course components in the following order: 1) watch the course presentation video; 2) complete the course evaluation; 3) pass the post-test with a score of 2/3 (66.7%) or higher. You may retake the post-test until a passing score is achieved, at which point you will be able to view/print a copy of your certificate of completion. This online certificate will also be saved within your profile 'My Dashboard' -> 'Transcript/Certificates Earned' for future access.
Designation Statement
NPACE designates this educational activity for a maximum of 1.50 contact hours, of which 1.25 is pharmacology credit. Participants should claim only credit commensurate with the extent of their participation in the activity.
Accreditation Statement
Nurse Practitioner Associates for Continuing Education (NPACE) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).
In addition to ANCC, NPACE is approved as a provider of continuing education in nursing by: the California Board of Registered Nursing, Provider Number CEP8720 and Florida CE Broker #50-1476.
Disclosure
Faculty
Contributing faculty, Josh Hamilton, DNP, RN-BC, FNP-C, PMHNP-BC, CNE, FAANP have disclosed:
Myriad Neuroscience, Speakers Bureau (ended 08/2023), PGx Testing Genesight
Tempus Labs, Inc., Consultant & Speakers Bureau, PGx Testing Tempus nP
Point of Care Network, Paid Ambassador, Various N/A
Planners
All planners and contributors involved in this educational activity have disclosed no relevant financial relationships.
Disclaimer
The material presented in this continuing education program is being made available for educational purposes only and is not intended to represent the best or only methods, medications and/or guidelines appropriate for the medical situation discussed. Rather the material is intended to present an approach, view, statement, or opinion of the presenter(s), which may be helpful, or of interest to other practitioners and should not be used by clinicians without the evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. NPACE disclaims any liability, loss, injury, or damage incurred as a consequence, directly or indirectly, of the use and application of any information given in a presentation.
Disclosure of Unlabeled Use
This educational activity may mention the uses of products that are not approved by the FDA for the indication(s) being discussed. The presenter(s) are instructed to notify participants when they are discussing unapproved uses or investigational agents. The opinions related to unapproved uses of products are solely those of the presenter(s) and are not endorsed or recommended by NPACE. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Commercial Support
There is no commercial support for this activity
Precision Medicine: Personalized Treatment of Depression
Pharmacogenomics is the study of how genes affect a person’s response to drugs. This science has given rise to the practice of “precision medicine,” which combines pharmacology (the study of medication) and genomics (the study of genes and their functions) to help prescribers make more personalized medication choices. These include which medications to prescribe to different individuals and what doses will have the best effects. This presentation integrates concepts of neurobiology and neuropathology with genetics and genomics to produce new models for diagnosis and personalized treatment for depressive disorders. The results of the GUIDED study are presented to highlight the efficacy of this approach.
Credits: 0.75 Contact Hours; 0.75 are Pharmacology
Learning Objectives
After taking part in this educational activity, participants should be better able to:
- Conceptualize mental illness in the context of epi/genetics and neurobiology, with an emphasis on depressive disorders.
- Discuss contemporary approaches to management of depressive disorders, including practical applications for nurse practitioners.
- Apply concepts of pharmacogenomics to the selection, prescription and management of drug therapy for depression.
Speaker
Josh Hamilton, DNP, RN-BC, FNP-C, PMHNP-BC, CTMH, CNE, FAANP
President & Chief Clinical Officer
The Hamilton Group LLC
CE Information
Obtain Your Credits
To earn credits for this activity, navigate to the Content(s) tab and complete all course components in the following order: 1) watch the course presentation video; 2) complete the course evaluation; 3) pass the post-test with a score of 2/3 (66.7%) or higher. You may retake the post-test until a passing score is achieved, at which point you will be able to view/print a copy of your certificate of completion. This online certificate will also be saved within your profile 'My Dashboard' -> 'Transcript/Certificates Earned' for future access.
Designation Statement
NPACE designates this educational activity for a maximum of 0.75 contact hours, of which 0.75 is pharmacology credit. Participants should claim only credit commensurate with the extent of their participation in the activity.
Accreditation Statement
Nurse Practitioner Associates for Continuing Education (NPACE) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).
In addition to ANCC, NPACE is approved as a provider of continuing education in nursing by: the California Board of Registered Nursing, Provider Number CEP8720 and Florida CE Broker #50-1476.
Disclosure
Faculty
Contributing faculty, Josh Hamilton, DNP, RN-BC, FNP-C, PMHNP-BC, CNE, FAANP have disclosed:
Myriad Neuroscience, Speakers Bureau (ended 08/2023), PGx Testing Genesight
Tempus Labs, Inc., Consultant & Speakers Bureau, PGx Testing Tempus nP
Point of Care Network, Paid Ambassador, Various N/A
Planners
All planners and contributors involved in this educational activity have disclosed no relevant financial relationships.
Disclaimer
The material presented in this continuing education program is being made available for educational purposes only and is not intended to represent the best or only methods, medications and/or guidelines appropriate for the medical situation discussed. Rather the material is intended to present an approach, view, statement, or opinion of the presenter(s), which may be helpful, or of interest to other practitioners and should not be used by clinicians without the evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. NPACE disclaims any liability, loss, injury, or damage incurred as a consequence, directly or indirectly, of the use and application of any information given in a presentation.
Disclosure of Unlabeled Use
This educational activity may mention the uses of products that are not approved by the FDA for the indication(s) being discussed. The presenter(s) are instructed to notify participants when they are discussing unapproved uses or investigational agents. The opinions related to unapproved uses of products are solely those of the presenter(s) and are not endorsed or recommended by NPACE. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Commercial Support
There is no commercial support for this activity
Neurobiology & Personalized Treatment of Anxiety Disorders
Updated diagnostic criteria and disease models for anxiety disorders are reviewed. Neurobiological and epigenetic mechanisms that underlie anxiety symptoms are presented as the basis for therapeutic interventions. Specific attention is given to the formulation of rational, genomically-informed pharmacologic treatment approaches for anxiety disorders. Practical applications for nurse practitioners are presented.
Credits: 1.00 Contact Hours; 1.00 are Pharmacology
Learning Objectives
After taking part in this educational activity, participants should be better able to:
- Develop a working knowledge of updated diagnostic criteria and disease models to improve case identification and diagnosis of anxiety disorders.
- Apply concepts of pharmacogenomics to the selection, prescription and management of drug therapy for anxiety disorders.
- Discuss contemporary approaches to management of anxiety disorders, including practical applications for nurse practitioners.
Speaker
Josh Hamilton, DNP, RN-BC, FNP-C, PMHNP-BC, CTMH, CNE, FAANP
President & Chief Clinical Officer
The Hamilton Group LLC
CE Information
Obtain Your Credits
To earn credits for this activity, navigate to the Content(s) tab and complete all course components in the following order: 1) watch the course presentation video; 2) complete the course evaluation; 3) pass the post-test with a score of 2/3 (66.7%) or higher. You may retake the post-test until a passing score is achieved, at which point you will be able to view/print a copy of your certificate of completion. This online certificate will also be saved within your profile 'My Dashboard' -> 'Transcript/Certificates Earned' for future access.
Designation Statement
NPACE designates this educational activity for a maximum of 1.00 contact hours, of which 1.00 is pharmacology credit. Participants should claim only credit commensurate with the extent of their participation in the activity.
Accreditation Statement
Nurse Practitioner Associates for Continuing Education (NPACE) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).
In addition to ANCC, NPACE is approved as a provider of continuing education in nursing by: the California Board of Registered Nursing, Provider Number CEP8720 and Florida CE Broker #50-1476.
Disclosure
Faculty
Contributing faculty, Josh Hamilton, DNP, RN-BC, FNP-C, PMHNP-BC, CNE, FAANP have disclosed:
Myriad Neuroscience, Speakers Bureau (ended 08/2023), PGx Testing Genesight
Tempus Labs, Inc., Consultant & Speakers Bureau, PGx Testing Tempus nP
Point of Care Network, Paid Ambassador, Various N/A
Planners
All planners and contributors involved in this educational activity have disclosed no relevant financial relationships.
Disclaimer
The material presented in this continuing education program is being made available for educational purposes only and is not intended to represent the best or only methods, medications and/or guidelines appropriate for the medical situation discussed. Rather the material is intended to present an approach, view, statement, or opinion of the presenter(s), which may be helpful, or of interest to other practitioners and should not be used by clinicians without the evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. NPACE disclaims any liability, loss, injury, or damage incurred as a consequence, directly or indirectly, of the use and application of any information given in a presentation.
Disclosure of Unlabeled Use
This educational activity may mention the uses of products that are not approved by the FDA for the indication(s) being discussed. The presenter(s) are instructed to notify participants when they are discussing unapproved uses or investigational agents. The opinions related to unapproved uses of products are solely those of the presenter(s) and are not endorsed or recommended by NPACE. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Commercial Support
There is no commercial support for this activity
To Prescribe or Not to Prescribe? Benzodiazepines in an Era of Prescription Drug Abuse
This presentation will focus on the class of anxiolytics known as the benzodiazepines. Over the years, prescribers have had a love/hate relationship with these controlled substances. Upon completion of this presentation, participants will learn the benefits and risks related to the safe prescribing of benzodiazepines for individuals with various symptom presentations. The presentation will address the risks and cautions related to the prescribing of benzodiazepines with various medications, including the opioids and stimulants and in various healthcare settings. Participants also will receive tips to identify the warning signs of benzodiazepine abuse and techniques to safely taper and discontinue these medications to minimize the discomfort of withdrawal.
Credits: 1.50 Contact Hours; 1.50 are Pharmacology
Learning Objectives
After taking part in this educational activity, participants should be better able to:
- Differentiate between FDA approved & off-label uses of benzodiazepines for varied symptom presentations
- Review and reconceptualize neurobiological mechanisms that underlie anxiety symptoms
- Identify & discuss the pharmacokinetics that lead to potential drug-drug interactions when patients concurrently use benzodiazepines with other medications
- Formulate rational, genomically-informed pharmacologic treatment approaches for anxiety disorders (including the appropriate use of benzodiazepines)
- Identify & discuss techniques to safely taper & discontinue benzodiazepines with minimal discomfort to the patient
Speaker
Josh Hamilton, DNP, RN-BC, FNP-C, PMHNP-BC, CTMH, CNE, FAANP
President & Chief Clinical Officer
The Hamilton Group LLC
CE Information
Obtain Your Credits
To earn credits for this activity, navigate to the Content(s) tab and complete all course components in the following order: 1) watch the course presentation video; 2) complete the course evaluation; 3) pass the post-test with a score of 2/3 (66.7%) or higher. You may retake the post-test until a passing score is achieved, at which point you will be able to view/print a copy of your certificate of completion. This online certificate will also be saved within your profile 'My Dashboard' -> 'Transcript/Certificates Earned' for future access.
Designation Statement
NPACE designates this educational activity for a maximum of 1.50 contact hours, of which 1.50 is pharmacology credit. Participants should claim only credit commensurate with the extent of their participation in the activity.
Accreditation Statement
Nurse Practitioner Associates for Continuing Education (NPACE) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).
In addition to ANCC, NPACE is approved as a provider of continuing education in nursing by: the California Board of Registered Nursing, Provider Number CEP8720 and Florida CE Broker #50-1476.
Disclosure
Faculty
Contributing faculty, Josh Hamilton, DNP, RN-BC, FNP-C, PMHNP-BC, CNE, FAANP have disclosed:
Myriad Neuroscience, Speakers Bureau (ended 08/2023), PGx Testing Genesight
Tempus Labs, Inc., Consultant & Speakers Bureau, PGx Testing Tempus nP
Point of Care Network, Paid Ambassador, Various N/A
Planners
All planners and contributors involved in this educational activity have disclosed no relevant financial relationships.
Disclaimer
The material presented in this continuing education program is being made available for educational purposes only and is not intended to represent the best or only methods, medications and/or guidelines appropriate for the medical situation discussed. Rather the material is intended to present an approach, view, statement, or opinion of the presenter(s), which may be helpful, or of interest to other practitioners and should not be used by clinicians without the evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. NPACE disclaims any liability, loss, injury, or damage incurred as a consequence, directly or indirectly, of the use and application of any information given in a presentation.
Disclosure of Unlabeled Use
This educational activity may mention the uses of products that are not approved by the FDA for the indication(s) being discussed. The presenter(s) are instructed to notify participants when they are discussing unapproved uses or investigational agents. The opinions related to unapproved uses of products are solely those of the presenter(s) and are not endorsed or recommended by NPACE. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Commercial Support
There is no commercial support for this activity
Neurobiology, Genomics & Precision Medicine for Bipolar Disorders
Updated disease models and diagnostic criteria for bipolar spectrum disorders are reviewed to improve case identification, diagnosis & treatment. Bipolar affective pathophysiology is redefined in the context of epigenetics and neurobiology, with specific attention to contemporary pharmacological approaches to manage bipolar disorders. Practical applications for nurse practitioners are presented.
Credits: 1.0 Contact Hours; 0.75 are Pharmacology
Learning Objectives
After taking part in this educational activity, participants should be better able to:
- Conceptualize mental illness in the context of epi/genetics and neurobiology, with an emphasis on bipolar spectrum disorders.
- Develop a working knowledge of updated diagnostic criteria and disease models to improve case identification and diagnosis of bipolar disorders.
- Discuss contemporary approaches to management of bipolar disorders, including practical applications for nurse practitioners.
- Explore evidence- and eminence-based polypharmaceutical approaches to selection and monitoring of treatments for mood instability.
- Apply concepts of pharmacogenomics to the selection, prescription and management of drug therapy for bipolar spectrum disorders.
Speaker
Josh Hamilton, DNP, RN-BC, FNP-C, PMHNP-BC, CTMH, CNE, FAANP
President & Chief Clinical Officer
The Hamilton Group LLC
CE Information
Obtain Your Credits
To earn credits for this activity, navigate to the Content(s) tab and complete all course components in the following order: 1) watch the course presentation video; 2) complete the course evaluation; 3) pass the post-test with a score of 2/3 (66.7%) or higher. You may retake the post-test until a passing score is achieved, at which point you will be able to view/print a copy of your certificate of completion. This online certificate will also be saved within your profile 'My Dashboard' -> 'Transcript/Certificates Earned' for future access.
Designation Statement
NPACE designates this educational activity for a maximum of 1.00 contact hours, of which 0.75 is pharmacology credit. Participants should claim only credit commensurate with the extent of their participation in the activity.
Accreditation Statement
Nurse Practitioner Associates for Continuing Education (NPACE) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).
In addition to ANCC, NPACE is approved as a provider of continuing education in nursing by: the California Board of Registered Nursing, Provider Number CEP8720 and Florida CE Broker #50-1476.
Disclosure
Faculty
Contributing faculty, Josh Hamilton, DNP, RN-BC, FNP-C, PMHNP-BC, CNE, FAANP have disclosed:
Myriad Neuroscience, Speakers Bureau (ended 08/2023), PGx Testing Genesight
Tempus Labs, Inc., Consultant & Speakers Bureau, PGx Testing Tempus nP
Point of Care Network, Paid Ambassador, Various N/A
Planners
All planners and contributors involved in this educational activity have disclosed no relevant financial relationships.
Disclaimer
The material presented in this continuing education program is being made available for educational purposes only and is not intended to represent the best or only methods, medications and/or guidelines appropriate for the medical situation discussed. Rather the material is intended to present an approach, view, statement, or opinion of the presenter(s), which may be helpful, or of interest to other practitioners and should not be used by clinicians without the evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. NPACE disclaims any liability, loss, injury, or damage incurred as a consequence, directly or indirectly, of the use and application of any information given in a presentation.
Disclosure of Unlabeled Use
This educational activity may mention the uses of products that are not approved by the FDA for the indication(s) being discussed. The presenter(s) are instructed to notify participants when they are discussing unapproved uses or investigational agents. The opinions related to unapproved uses of products are solely those of the presenter(s) and are not endorsed or recommended by NPACE. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Commercial Support
There is no commercial support for this activity
Precision Medicine for ADHD: Genetics, Neurobiology & Treatment
This presentation discusses updated diagnostic criteria and psychometric approaches to improve case identification, diagnosis & treatment of attention deficit-hyperactivity disorders. ADHD is redefined in the context of epigenetics and neurobiology, with specific attention to contemporary pharmacological approaches to manage the symptoms. Practical applications for nurse practitioners are presented.
Credits: 1.0 Contact Hours; 1.00 are Pharmacology
Learning Objectives
After taking part in this educational activity, participants should be better able to:
- Conceptualize mental illness in the context of epi/genetics and neurobiology, with an emphasis on attention-deficit disorders
- Develop a working knowledge of updated criteria and psychometry to improve case identification and diagnosis of attention-deficit disorders
- Discuss contemporary approaches to management of attention-deficit disorders, including practical applications for nurse practitioners
- Apply concepts of pharmacogenomics to the selection, prescription, and management of drug therapy for disorders of inattention and hyperactivity
Speaker
Josh Hamilton, DNP, RN-BC, FNP-C, PMHNP-BC, CTMH, CNE, FAANP
President & Chief Clinical Officer
The Hamilton Group LLC
CE Information
Obtain Your Credits
To earn credits for this activity, navigate to the Content(s) tab and complete all course components in the following order: 1) watch the course presentation video; 2) complete the course evaluation; 3) pass the post-test with a score of 2/3 (66.7%) or higher. You may retake the post-test until a passing score is achieved, at which point you will be able to view/print a copy of your certificate of completion. This online certificate will also be saved within your profile 'My Dashboard' -> 'Transcript/Certificates Earned' for future access.
Designation Statement
NPACE designates this educational activity for a maximum of 1.00 contact hours, of which 1.00 is pharmacology credit. Participants should claim only credit commensurate with the extent of their participation in the activity.
Accreditation Statement
Nurse Practitioner Associates for Continuing Education (NPACE) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).
In addition to ANCC, NPACE is approved as a provider of continuing education in nursing by: the California Board of Registered Nursing, Provider Number CEP8720 and Florida CE Broker #50-1476.
Disclosure
Faculty
Contributing faculty, Josh Hamilton, DNP, RN-BC, FNP-C, PMHNP-BC, CNE, FAANP have disclosed:
Myriad Neuroscience, Speakers Bureau (ended 08/2023), PGx Testing Genesight
Tempus Labs, Inc., Consultant & Speakers Bureau, PGx Testing Tempus nP
Point of Care Network, Paid Ambassador, Various N/A
Planners
All planners and contributors involved in this educational activity have disclosed no relevant financial relationships.
Disclaimer
The material presented in this continuing education program is being made available for educational purposes only and is not intended to represent the best or only methods, medications and/or guidelines appropriate for the medical situation discussed. Rather the material is intended to present an approach, view, statement, or opinion of the presenter(s), which may be helpful, or of interest to other practitioners and should not be used by clinicians without the evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. NPACE disclaims any liability, loss, injury, or damage incurred as a consequence, directly or indirectly, of the use and application of any information given in a presentation.
Disclosure of Unlabeled Use
This educational activity may mention the uses of products that are not approved by the FDA for the indication(s) being discussed. The presenter(s) are instructed to notify participants when they are discussing unapproved uses or investigational agents. The opinions related to unapproved uses of products are solely those of the presenter(s) and are not endorsed or recommended by NPACE. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Commercial Support
There is no commercial support for this activity
Bundle Evaluation & Certificate: Mental Health, Advanced Pharmacotherapeutics, & Precision Medicine Bundle 2024
Complete this evaluation to earn your certificate of completion in Mental Health Pharmacotheraputics and Precision medicine.